Biogen Inc. (FRA:IDP)

Marathon Oil Statistics

Total Valuation

Biogen has a market cap or net worth of EUR 16.76 billion. The enterprise value is 20.08 billion.

Market Cap	16.76B
Enterprise Value	20.08B

Important Dates

The last earnings date was Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.61M
Shares Outstanding	n/a
Shares Change (YoY)	+0.31%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.13M

Valuation Ratios

The trailing PE ratio is 12.86 and the forward PE ratio is 8.73.

PE Ratio	12.86
Forward PE	8.73
PS Ratio	1.97
PB Ratio	1.12
P/TBV Ratio	11.76
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.94, with an EV/FCF ratio of 11.92.

EV / Earnings	15.41
EV / Sales	2.32
EV / EBITDA	6.94
EV / EBIT	9.35
EV / FCF	11.92

Financial Position

The company has a current ratio of 2.50, with a Debt / Equity ratio of 0.37.

Current Ratio	2.50
Quick Ratio	1.52
Debt / Equity	0.37
Debt / EBITDA	1.97
Debt / FCF	3.33
Interest Coverage	9.82

Financial Efficiency

Return on equity (ROE) is 9.13% and return on invested capital (ROIC) is 6.62%.

Return on Equity (ROE)	9.13%
Return on Assets (ROA)	5.62%
Return on Invested Capital (ROIC)	6.62%
Return on Capital Employed (ROCE)	9.85%
Revenue Per Employee	1.12M
Profits Per Employee	171,364
Employee Count	7,605
Asset Turnover	0.36
Inventory Turnover	1.02

Taxes

In the past 12 months, Biogen has paid 227.52 million in taxes.

Income Tax	227.52M
Effective Tax Rate	14.86%

Stock Price Statistics

The stock price has decreased by -43.14% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-43.14%
50-Day Moving Average	112.35
200-Day Moving Average	130.30
Relative Strength Index (RSI)	45.30
Average Volume (20 Days)	188

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.66

Income Statement

In the last 12 months, Biogen had revenue of EUR 8.51 billion and earned 1.30 billion in profits. Earnings per share was 8.90.

Revenue	8.51B
Gross Profit	6.43B
Operating Income	2.11B
Pretax Income	1.53B
Net Income	1.30B
EBITDA	2.74B
EBIT	2.11B
Earnings Per Share (EPS)	8.90

Balance Sheet

The company has 2.35 billion in cash and 5.62 billion in debt, giving a net cash position of -3.27 billion.

Cash & Cash Equivalents	2.35B
Total Debt	5.62B
Net Cash	-3.27B
Net Cash Per Share	n/a
Equity (Book Value)	15.02B
Book Value Per Share	102.42
Working Capital	4.07B

Cash Flow

In the last 12 months, operating cash flow was 1.80 billion and capital expenditures -117.51 million, giving a free cash flow of 1.68 billion.

Operating Cash Flow	1.80B
Capital Expenditures	-117.51M
Free Cash Flow	1.68B
FCF Per Share	n/a

Margins

Gross margin is 75.58%, with operating and profit margins of 24.79% and 15.31%.

Gross Margin	75.58%
Operating Margin	24.79%
Pretax Margin	17.98%
Profit Margin	15.31%
EBITDA Margin	32.23%
EBIT Margin	24.79%
FCF Margin	19.79%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.31%
Shareholder Yield	n/a
Earnings Yield	7.78%
FCF Yield	10.06%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on January 18, 2001. It was a forward split with a ratio of 3.

Last Split Date	Jan 18, 2001
Split Type	Forward
Split Ratio	3

Scores

Biogen has an Altman Z-Score of 3.16 and a Piotroski F-Score of 6.

Altman Z-Score	3.16
Piotroski F-Score	6